Bayer AG has been experiencing a tumultuous period, with shares slumping to a 20-year low. The company's 2025 earnings fall forecast and recent outlook cuts led to the decrease. Even its Q3 earnings were not satisfactory with considerable losses and a wary outlook for future performance. Bayer's performance provoked shareholders to demand faster changes to stop the influx of bad news. Though the company's shares surged after it won a legal battle over Roundup, a weedkiller manufactured by its subsidiary Monsanto, but the stock was later negatively affected as the case was approved for review by the U.S Court. However, Bayer did record some positive events such as the promising results for Kerendia in phase 3 heart failure study, a partnership with OneMedNet to power AI medical imaging innovation and its subsidiary Vividion's acquisition of the US based biotech firm, Tavros. Yet, despite these promising endeavors, Bayer's shares remain volatile, facing continuous fluctuations in their value.
BAYER Stocks News Analytics from Tue, 28 Nov 2023 08:00:00 GMT to Thu, 27 Feb 2025 06:53:42 GMT - Rating -5 - Innovation -4 - Information 6 - Rumor -8